文献速递胸部肿瘤

TP53共突变增加EGFR突变I期肺腺癌复发风险

TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma.
PubMed 文献 · Eur J Cancer · 2025-07-10

在两家高容量中心接受根治性手术的370例I期肺腺癌患者中,97例存在EGFR突变;McGill/IRE队列中EGFR+TP53共突变患者无复发生存期(RFS)显著差于单纯EGFR突变患者(p=0.001),多因素分析中EGFR+TP53共突变与更差RFS显著相关(HR 5.32);MSKCC队列中该共突变与更短RFS及相似总生存相关。

要点

  • I期肺腺癌根治术后EGFR+TP53共突变者RFS显著更差(p=0.001)。
  • 多因素分析显示EGFR+TP53共突变与更差RFS显著相关(HR 5.32)。
  • MSKCC队列中EGFR+TP53共突变与更短RFS及相似OS相关。

核心结论

  • 在EGFR突变、已切除的I期肺腺癌患者中,TP53共突变的存在与更差的无复发生存期相关。

研究设计与样本

  • 收集两家高容量中心接受根治性手术治疗且术后分子检测可用的I期肺腺癌患者,共纳入370例,其中97例存在EGFR突变。
  • 采用Kaplan-Meier乘积极限法估计生存曲线并以log-rank检验比较,采用多因素Cox回归分析临床与生物学变量与RFS的关联,结果以风险比及其95%置信区间报告;并利用公开数据集(OncoSG、MSK-LUAD604)在外部队列中进一步检验假设。

主要发现

  • McGill/IRE队列中,EGFR+TP53共突变患者RFS较EGFR突变肺腺癌患者显著更差(p=0.001)。
  • 多因素分析中,EGFR+TP53共突变与更差RFS显著相关(HR 5.32)。
  • MSKCC队列中,EGFR+TP53共突变与更短RFS及相似OS相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Adjuvant osimertinib was shown to improve survival outcomes in resected, EGFR mutated, stage IB-IIIA NSCLC. However, the prognostic implications of co-occurring mutations in resected, stage I tumours are unclear. Due to the poor prognosis of EGFR/TP53 co-mutations in patients with advanced NSCLC, we focused on this event in a cohort of patients with untreated, resected-stage I-LUAD. METHODS: Patients who underwent radical surgical treatment for stage I LUAD in two high volume centers with available postoperative molecular testing were collected. Survival curves were estimated using the Kaplan-Meier product-limit method and were compared using the log-rank test; multivariable Cox regression analyses were used to assess the association between clinical and biological variables and RFS, and results were reported in the form of hazard ratios and their 95 % confidence intervals. We then leveraged publicly available datasets (OncoSG, MSK-LUAD604) to further test the hypothesis in external cohorts. RESULTS: A total of 370 patients were included from two high volume centers of which 97 had an EGFR mutation. In the McGill/IRE cohort, patients with EGFR+TP53 co-mutation had a significantly worse RFS when compared to patients with EGFR-mutated LUAD (p = 0.001). In the multivariable analysis, EGFR+TP53 co-mutations (HR 5.32) were significantly associated with worse RFS. In the MSKCC cohort, EGFR+TP53 co-mutations were associated with shorter RFS and similar OS. CONCLUSION: Our results suggest that, among patients with EGFR-mutated, resected-stage I-LUAD, the presence of a TP53 co-mutation is associated with worse RFS. These findings corroborate the aggressive biology associated with these molecular findings in patients with metastatic, EGFR-mutated LUAD.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gallina FT, Marinelli D, Tajè R, et al. TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma. Eur J Cancer. 2025. PMID: 40680467. doi:10.1016/j.ejca.2025.115622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。